MDxHealth SA is a precision diagnostics company that focuses on developing and commercializing innovative molecular tests to support the diagnosis, prognosis, and monitoring of cancer. Through its proprietary technology and advanced genomic profiling, the company aims to provide healthcare professionals with critical insights into patient conditions, ultimately enhancing personalized treatment strategies. MDxHealth’s products are designed to improve patient outcomes by offering more accurate and reliable information that assists in clinical decision-making in oncology. Read More
August 14, 2026 - VivoSim Labs, Inc. (NASDAQ: VIVS) is emerging at the intersection of artificial intelligence, biotechnology, drug development, 3D human tissue models and New Approach Methodologies (NAMs) as pharmaceutical companies face increasing pressure to identify costly drug toxicity problems earlier in the development process.
Aug. 14, 2026 — Kartoon Studios, Inc. (NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
On Thursday, MDxHealth (NASDAQ:MDXH) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts and
IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostic
